Cipla Stock Surges Above 4% as Citi Boosts Pharma Giant, Eyes Near-Term US Triggers
Shares of Cipla surged over 4 percent on Monday, emerging as one of the top performers in the Nifty indices. The stock traded at Rs 1,407 following a rating reinforcement from Citibank (Citi), which placed the pharmaceutical major on a list of near-term positive catalyst stocks.The brokerage maintained its target price for Cipla at Rs 1,700. This suggests significant potential upside of 26 percent from current trading levels. Citi believes that several key factors point towards a favorable rebound in the company's crucial US business operations.
Near-Term Catalysts Drive Citi’s Positive Outlook
Citi identified multiple near-term triggers set to fuel Cipla's growth trajectory. These include the potential gFlovent approval and the upcoming launch of gVentolin. Furthermore, Cipla’s established position in Nintedanib is viewed positively by the brokerage house.Improving prospects have also been noted within the domestic market segment. The respiratory division of the company, specifically, shows signs of a robust recovery trend. An additional boost could come if the upcoming re-inspection of the Indore facility leads to full USFDA clearance.
Financial Health and Valuation Perspective
Citi noted that earnings for Cipla are likely to have bottomed out following declines in gRevlimid related revenues. The brokerage maintains that the risk-reward profile remains favourable despite the current valuation metrics.Despite the stock trading at 25 times FY27 estimated earnings and 21 times FY28 estimated earnings, Citi views Cipla as a compelling domestic healthcare play. This perspective is bolstered by the likelihood of reduced pressure on input costs and margins due to easing geopolitical tensions.
Quarterly Performance and Future Guidance
The positive brokerage action comes a month after Cipla reported its March-quarter results. The company posted revenue from operations amounting to Rs 6,541 crore. However, net profit for the quarter saw a decline of 55 percent year on year, settling at Rs 554.6 crore.Looking ahead, the company’s revenue was projected at Rs 28,163 crore for FY26. Net profit for FY26 is estimated at Rs 3,862 crore. Furthermore, the board recommended a final dividend of Rs 13 per share for the financial year.
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.